Alcon Stock - Analyst consensus and sector context at week’s end
19.06.2026 - 14:55:10 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 14:51 CET. Details in the imprint.
Alcon (CH0432492467) remains one of the larger pure-play eye-care names in European medtech. With no fresh company news this week from the investor relations page or major wires, the focus shifts to how the stock sits in analyst models and within its sector.
All news and key data on Alcon stock
Further background, regulatory filings and historic price data on Alcon are bundled in the dedicated topic section and on the company’s investor relations page.
How Alcon shares have traded
Alcon shares are quoted on SIX Swiss Exchange in Zurich under the ticker ALC and trade in Swiss francs. According to a recent quote snapshot, the stock changed hands at around CHF 52.82 during Friday morning trading on the Swiss market.
That level leaves the shares some way below their 52-week high above CHF 70, reached earlier in the year before a softer phase for many medtech names. The current price range reflects a more cautious stance toward higher-valuation growth stocks in a context of still-elevated interest rates.
Analyst views and consensus numbers
Consensus data compiled by MarketScreener show that the majority of covering analysts retain Buy or Outperform ratings on Alcon, with only a small minority at Hold and virtually none at Sell. The aggregated 12-month price target stands in the mid-CHF 70s, implying notable upside from current levels.
Forecasts for the current financial year point to mid-single-digit to high-single-digit organic revenue growth and a gradual improvement in operating margin. Analysts cite continued penetration of premium intraocular lenses and growth in contact lenses and surgical equipment as core drivers for the model.
Weekly snapshot against medtech peers
Against other large European health-care equipment names, Alcon’s share performance over the last year has been mixed. The stock is down double digits on a 12-month view, while some diversified peers have held up better as investors rotated into broader exposure.
At the same time, the company’s focus on eye care sets it apart from conglomerate-style medtech groups. Net-net, the valuation discount versus a few peers partly reflects execution risk and the need to demonstrate sustained margin expansion, not doubts about the structural demand for ophthalmic care.
How the company makes money
Alcon generates most of its revenue from ophthalmic products, split primarily between Surgical and Vision Care businesses. The portfolio spans intraocular lenses used in cataract surgery, including premium presbyopia-correcting lenses, as well as contact lenses and ocular health products aimed at consumers and eye-care professionals.
Where the stock trades today
The shares of Alcon (CH0432492467) trade on SIX Swiss Exchange in Zurich at CHF 52.82 as of 06/19/2026, 10:10 CET.
Key facts on Alcon stock
- Company: Alcon Inc.
- ISIN: CH0432492467
- WKN: A2PA9E
- Ticker: ALC
- Venue: SIX Swiss Exchange (Zurich)
- Price (as of 06/19/2026, 10:10 CET): 52.82 CHF
- Market cap: 25,000,000,000 CHF (as of 06/19/2026, approximate)
- Sector / Industry: Health Care - Medical Equipment & Supplies
- Index membership: Part of major Swiss and European health-care indices
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
